Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 6/20 | 0.36 |
| ▸ | RAB9A | P51151 | 6/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27396560 | 0.98 | GAA (0.46) | GAAALDH1A1TSHRPTPN1NPC1 | |
| SCHEMBL2092228 | 0.79 | METAP2 (0.34) | METAP2 | |
| SCHEMBL500129 | 0.78 | ALOX15 (0.41) | ALDH1A1TSHRNPC1RAB9AKDM4E | |
| SCHEMBL28769696 | 0.75 | NOTUM (0.40) | PTPN1NPC1RAB9AMAPTKDM4E | |
| SCHEMBL2751295 | 0.67 | PDE4A (0.56) | ALDH1A1NPC1RAB9AMAPTKDM4E | |
| SCHEMBL3608419 | 0.65 | GAA (0.41) | GAAALDH1A1TSHRPTPN1NPC1 | |
| SCHEMBL5963207 | 0.64 | ALDH1A1 (0.58) | GAAALDH1A1TSHRNPC1RAB9A | |
| SCHEMBL102644 | 0.64 | GAA (1.00) | GAAALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL14710357 | 0.64 | GAA (0.48) | GAAALDH1A1TSHRPTPN1NPC1 | |
| SCHEMBL6608660 | 0.62 | GAA (0.96) | GAAALDH1A1NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6083945-A | USEFUL IN TREATING HUMANS OR OTHER MAMMALS WITH CARDIAC ARRHYTHMIA AND/OR CARDIAC FIBRILLATION | THE PROCTER & GAMBLE COMPANY (US) | 2000-07-04 | — | — | US | claimed |
| US-5691369-A | CARDIOVASCULAR DISORDERS | THE PROCTOR & GAMBLE COMPANY (US) | 1997-11-25 | — | — | US | claimed |
| US-8586770-B2 | Unsaturated steroid compounds | Harbor Therapeutics, Inc. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20120029260-A1 | Screening and Treatment Method | BIOVIE INC. | 2012-02-02 | — | — | US | disclosed |
| US-20110137057-A1 | Unsaturated Steroid Compounds | BIOVIE INC. | 2011-06-09 | — | — | US | disclosed |
| US-20110085984-A1 | Drug Product and Process for Making | BIOVIE INC. | 2011-04-14 | — | — | US | disclosed |
| US-7910755-B2 | Stem cell expansion and uses | HARBOR BIOSCIENCES, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| CN-100497345-C | 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2009-06-10 | — | — | CN | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-5994354-A | Cyclic urethanes useful as antiarrhythmic and antifibrillatory agents | THE PROCTER & GAMBLE COMPANY (US) | 1999-11-30 | — | — | US | disclosed |
| EP-0957103-A1 | Oxazolidinone derivatives useful as antiarrhythmic and antifibrillatory agents | Procter & Gamble Pharmaceuticals, Inc. (US) | 1999-11-17 | — | — | EP | disclosed |
| EP-0891976-A1 | Novel cyclic ureas useful as antiarrhythmic and antifibrillatory agents | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1999-01-20 | — | — | EP | disclosed |
| US-5691369-A | CARDIOVASCULAR DISORDERS | THE PROCTOR & GAMBLE COMPANY (US) | 1997-11-25 | — | — | US | disclosed |
| US-5462940-A | 4-oxocyclic ureas useful as antiarrhythmic and antifibrillatory agents | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0599968-A1 | CYCLIC URETHANES USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1994-06-08 | — | — | EP | disclosed |
| EP-0598061-A1 | NOVEL 4-OXOCYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1994-05-25 | — | — | EP | disclosed |
| WO-1993004064-A1 | CYCLIC URETHANES USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-03-04 | — | — | WO | disclosed |
| WO-1993004061-A1 | NOVEL 4-OXOCYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1993-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | GAA 3982/4885ALDH1A1 412/4885TSHR 162/4885 |
| US-20110085984-A1 | Drug Product and Process for Making | CYP2D6, CYP3A5, CYP2B6 | GAA 556/4885ALDH1A1 187/4885TSHR 2374/4885 |
| US-20110137057-A1 | Unsaturated Steroid Compounds | SREBF1, SREBF2, NR1H3 | GAA 4710/4885ALDH1A1 257/4885TSHR 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.